Psychopharmacological Neuroprotection in Neurodegenerative Diseases, Part III: Criteria-Based Assessment: A Report of the ANPA Committee on Research

摘要

Neurodegenerative diseases (NDDs) are common and impose substantial morbidities and costs on patients, caregivers, and society.1 The two most common, Alzheimer's disease (AD) and Parkinson's disease (PD), affect more than 5 million people in the United States and are exponentially increasing with population demographic trends;2 and they result in considerable morbidities and costs.3 Neuropsychiatric disturbances are prominent among these morbidities and can contribute significantly to quality of life in NDDs.